The effect of PI3K pathway inhibitor and chemical epigenetics in angiosarcoma cells
| Project/Area Number |
16K19735
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Dermatology
|
|---|
| Research Institution | Kyoto Prefectural University of Medicine |
|---|
Principal Investigator |
Wada Makoto 京都府立医科大学, 医学(系)研究科(研究院), 学内講師 (90733080)
|
|---|
| Project Period (FY) |
2016-04-01 – 2018-03-31
|
| Project Status |
Completed (Fiscal Year 2017)
|
| Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2017: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2016: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Keywords | 血管肉腫 / PI3K阻害剤 / HDAC阻害剤 / PI3K/mTOR阻害剤 / PI3K経路阻害剤 / エピジェネティクス制御化合物 |
|---|
| Outline of Final Research Achievements |
In this study, we evaluated the growth inhibition of PI3K inhibitor and epigenetics compounds in angiosarcoma cells. Histone deacetylase(HDAC) inhibitors suppressed the growth of angiosarcoma cells. HDAC inhibitors induced the cell-cycle arrest at G1 phase with the downregulated expression of cyclinD1 in ISOS-1 cells, and induced the cell-cycle arrest in G2/M phase with the upregulated expression of p21 in ISO-HAS cells. The combination of PI3K inhibitor and HDAC inhibitor additively suppressed the growth of angiosarcoma cells
|
Report
(3 results)
Research Products
(1 results)
